Genomic Landscape of Branchio-Oto-Renal Syndrome through Whole-Genome Sequencing: A Single Rare Disease Center Experience in South Korea
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25158149 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Sung Ho Cho und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 030…. Hauptthemen laut MEDLINE: Branchio-Oto-Renal Syndrome, Whole Genome Sequencing, DNA Copy Number Variations. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SNUH Kun-hee Lee Child Cancer & Rare Disease Project, Republic of Korea, SNUH Kun-hee Lee Child Cancer & Rare Disease Project, Republic of Korea, National Research Foundation of Korea (NRF).
Abstract (Originalsprache)
Branchio-oto-renal (BOR) and branchio-otic (BO) syndromes are characterized by anomalies affecting the ears, often accompanied by hearing loss, as well as abnormalities in the branchial arches and renal system. These syndromes exhibit a broad spectrum of phenotypes and a complex genomic landscape, with significant contributions from the EYA1 gene and the SIX gene family, including SIX1 and SIX5. Due to their diverse phenotypic presentations, which can overlap with other genetic syndromes, molecular genetic confirmation is essential. As sequencing technologies advance, whole-genome sequencing (WGS) is increasingly used in rare disease diagnostics. We explored the genomic landscape of 23 unrelated Korean families with typical or atypical BOR/BO syndrome using a stepwise approach: targeted panel sequencing and exome sequencing (Step 1), multiplex ligation-dependent probe amplification (MLPA) with copy number variation screening (Step 2), and WGS (Step 3). Integrating WGS into our diagnostic pipeline detected structure variations, including cryptic inversion and complex genomic rearrangement, eventually enhancing the diagnostic yield to 91%. Our findings expand the genomic architecture of BOR/BO syndrome and highlight the need for WGS to address the genetic diagnosis of clinically heterogeneous rare diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
- Department of Genomic Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
- Sensory Organ Research Institute, Seoul National University Medical Research Center, Seoul 03080, Republic of Korea.
ORCID-Profile: Sung Ho Jeong
Förderung
- SNUH Kun-hee Lee Child Cancer & Rare Disease Project, Republic of Korea
- SNUH Kun-hee Lee Child Cancer & Rare Disease Project, Republic of Korea
- National Research Foundation of Korea (NRF)
- Ministry of Education
- SNU Medicine
- SNUH Research Fund
Zitieren
APA
Cho, S. H., Jeong, S. H., Choi, W. H., & Lee, S. Y. (2024). Genomic Landscape of Branchio-Oto-Renal Syndrome through Whole-Genome Sequencing: A Single Rare Disease Center Experience in South Korea. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25158149
Vancouver
Cho SH, Jeong SH, Choi WH, Lee SY. Genomic Landscape of Branchio-Oto-Renal Syndrome through Whole-Genome Sequencing: A Single Rare Disease Center Experience in South Korea. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25158149
BibTeX
@article{Cho2024,
author = {Cho, Sung Ho and Jeong, Sung Ho and Choi, Won Hoon and Lee, Sang-Yeon},
title = {Genomic Landscape of Branchio-Oto-Renal Syndrome through Whole-Genome Sequencing: A Single Rare Disease Center Experience in South Korea},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25158149}
}
EUVIMED